TY  - GEN
AU  - Shafran,S D
AU  - Shaw,D
AU  - Charafeddine,M
AU  - Agarwal,K
AU  - Foster,G R
AU  - Abunimeh,M
AU  - Pilot-Matias,T
AU  - Pothacamury,R K
AU  - Fu,B
AU  - Cohen,E
AU  - Cohen,D E
AU  - Gane,E
TI  - Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
SN  - 1365-2893
PY  - 2019///0318
KW  - Adult
KW  - Aged
KW  - Anilides
KW  - administration & dosage
KW  - Antiviral Agents
KW  - Carbamates
KW  - Cyclopropanes
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C
KW  - drug therapy
KW  - Humans
KW  - Lactams, Macrocyclic
KW  - Liver Cirrhosis
KW  - Macrocyclic Compounds
KW  - Male
KW  - Middle Aged
KW  - Proline
KW  - analogs & derivatives
KW  - RNA, Viral
KW  - blood
KW  - Ribavirin
KW  - Ritonavir
KW  - Sofosbuvir
KW  - Sulfonamides
KW  - Sustained Virologic Response
KW  - Treatment Outcome
KW  - Valine
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/jvh.12782
ER  -